{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:16:54Z","timestamp":1794410214439,"version":"4.9.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["821704730"],"award-info":[{"award-number":["821704730"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021CX020227"],"award-info":[{"award-number":["2021CX020227"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54462-0","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T05:44:55Z","timestamp":1732340695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-8546","authenticated-orcid":false,"given":"Yongzhi","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1648-4189","authenticated-orcid":false,"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-4634","authenticated-orcid":false,"given":"Ting","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunzhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miru","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-6137","authenticated-orcid":false,"given":"Wei K.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0814","authenticated-orcid":false,"given":"Deyin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-8155","authenticated-orcid":false,"given":"Xinwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-8333","authenticated-orcid":false,"given":"Hongming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-1544","authenticated-orcid":false,"given":"Jinsai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"54462_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"54462_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med"},{"key":"54462_CR3","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433 e2413 (2022).","journal-title":"Cell"},{"key":"54462_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"54462_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1473-3099(22)00410-8","volume":"22","author":"L Yao","year":"2022","unstructured":"Yao, L. et al. Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect. Dis. 22, 1116\u20131117 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"54462_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med"},{"key":"54462_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12250-015-3711-3","volume":"31","author":"H Wang","year":"2016","unstructured":"Wang, H., Xue, S., Yang, H. & Chen, C. Recent progress in the discovery of inhibitors targeting coronavirus proteases. Virol. Sin. 31, 24\u201330 (2016).","journal-title":"Virol. Sin."},{"key":"54462_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103832","volume":"29","author":"X Li","year":"2024","unstructured":"Li, X. & Song, Y. Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery. Drug Discov. Today 29, 103832 (2024).","journal-title":"Drug Discov. Today"},{"key":"54462_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20542-0","volume":"12","author":"G Kokic","year":"2021","unstructured":"Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, 279 (2021).","journal-title":"Nat. Commun."},{"key":"54462_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N. Engl. J. Med. 386, 509\u2013520 (2022).","journal-title":"N. Engl. J. Med"},{"key":"54462_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N. Engl. J. Med. 388, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med"},{"key":"54462_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel, R. et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N. Engl. J. Med. 387, 790\u2013798 (2022).","journal-title":"N. Engl. J. Med"},{"key":"54462_CR13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae, H. et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2\/3 Study. Clin. Infect. Dis. 76, 1403\u20131411 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"54462_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01115-23","volume":"68","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171. Antimicrob. Agents Chemother. 68, e0111523 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54462_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Preclinical evaluation of the SARS-CoV-2 M(pro) inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat. Microbiol 9, 1075\u20131088 (2024).","journal-title":"Nat. Microbiol"},{"key":"54462_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42102-y","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang, X. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 14, 6463 (2023).","journal-title":"Nat. Commun."},{"key":"54462_CR17","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","volume":"399","author":"WHOST Consortium","year":"2022","unstructured":"Consortium, W. H. O. S. T. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399, 1941\u20131953 (2022).","journal-title":"Lancet"},{"key":"54462_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100735","volume":"3","author":"A Heyer","year":"2022","unstructured":"Heyer, A. et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med 3, 100735 (2022).","journal-title":"Cell Rep. Med"},{"key":"54462_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/cid\/ciac769","volume":"76","author":"JI Hogan","year":"2023","unstructured":"Hogan, J. I. et al. Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019. Clin. Infect. Dis. 76, 342\u2013345 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"54462_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29104-y","volume":"13","author":"S Gandhi","year":"2022","unstructured":"Gandhi, S. et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat. Commun. 13, 1547 (2022).","journal-title":"Nat. Commun."},{"key":"54462_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/cid\/ciac180","volume":"76","author":"LD Saravolatz","year":"2023","unstructured":"Saravolatz, L. D., Depcinski, S. & Sharma, M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clin. Infect. Dis. 76, 165\u2013171 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"54462_CR22","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","volume":"65","author":"H Tan","year":"2022","unstructured":"Tan, H., Hu, Y., Jadhav, P., Tan, B. & Wang, J. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. J. Med Chem. 65, 7561\u20137580 (2022).","journal-title":"J. Med Chem."},{"key":"54462_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40261-023-01265-8","volume":"43","author":"R Shimizu","year":"2023","unstructured":"Shimizu, R. et al. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Clin. Drug Investig. 43, 335\u2013346 (2023).","journal-title":"Clin. Drug Investig."},{"key":"54462_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00632-22","volume":"66","author":"R Shimizu","year":"2022","unstructured":"Shimizu, R. et al. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrob. Agents Chemother. 66, e0063222 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54462_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"54462_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"YM B\u00e1ez-Santos","year":"2015","unstructured":"B\u00e1ez-Santos, Y. M., St John, S. E. & Mesecar, A. D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antivir. Res. 115, 21\u201338 (2015).","journal-title":"Antivir. Res"},{"key":"54462_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662 (2020).","journal-title":"Nature"},{"key":"54462_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.add0082","volume":"16","author":"D Cao","year":"2023","unstructured":"Cao, D. et al. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING. Sci. Signal 16, eadd0082 (2023).","journal-title":"Sci. Signal"},{"key":"54462_CR29","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia, K. et al. A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl Acad. Sci. USA 105, 16119\u201316124 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54462_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.virol.2022.07.006","volume":"574","author":"H Yan","year":"2022","unstructured":"Yan, H. et al. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors. Virology 574, 18\u201324 (2022).","journal-title":"Virology"},{"key":"54462_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21060-3","volume":"12","author":"J Osipiuk","year":"2021","unstructured":"Osipiuk, J. et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 12, 743 (2021).","journal-title":"Nat. Commun."},{"key":"54462_CR32","first-page":"17","volume":"14","author":"Y Zang","year":"2023","unstructured":"Zang, Y. et al. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors. Protein Cell 14, 17\u201327 (2023).","journal-title":"Protein Cell"},{"key":"54462_CR33","doi-asserted-by":"publisher","unstructured":"Wang, Q. et al. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms24108633 (2023).","DOI":"10.3390\/ijms24108633"},{"key":"54462_CR34","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","volume":"65","author":"Z Shen","year":"2022","unstructured":"Shen, Z. et al. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. J. Med Chem. 65, 2940\u20132955 (2022).","journal-title":"J. Med Chem."},{"key":"54462_CR35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s13238-022-00909-3","volume":"13","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell 13, 940\u2013953 (2022).","journal-title":"Protein Cell"},{"key":"54462_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","volume":"11","author":"X Gao","year":"2021","unstructured":"Gao, X. et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm. Sin. B 11, 237\u2013245 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"54462_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","volume":"7","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent. Sci. 7, 1245\u20131260 (2021).","journal-title":"ACS Cent. Sci."},{"key":"54462_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116011","volume":"264","author":"P Jadhav","year":"2024","unstructured":"Jadhav, P. et al. Structure-based design of SARS-CoV-2 papain-like protease inhibitors. Eur. J. Med Chem. 264, 116011 (2024).","journal-title":"Eur. J. Med Chem."},{"key":"54462_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37254-w","volume":"14","author":"BC Sanders","year":"2023","unstructured":"Sanders, B. C. et al. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nat. Commun. 14, 1733 (2023).","journal-title":"Nat. Commun."},{"key":"54462_CR40","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.adm9724","volume":"383","author":"B Tan","year":"2024","unstructured":"Tan, B. et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434\u20131440 (2024).","journal-title":"Science"},{"key":"54462_CR41","unstructured":"Garnsey, M. R. et al. Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model. bioRxiv (2024)."},{"key":"54462_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.876212","volume":"10","author":"DJ Calleja","year":"2022","unstructured":"Calleja, D. J., Lessene, G. & Komander, D. Inhibitors of SARS-CoV-2 PLpro. Front Chem. 10, 876212 (2022).","journal-title":"Front Chem."},{"key":"54462_CR43","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1021\/jacs.3c04115","volume":"145","author":"Y Shiraishi","year":"2023","unstructured":"Shiraishi, Y. & Shimada, I. NMR Characterization of the Papain-like Protease from SARS-CoV-2 Identifies the Conformational Heterogeneity in Its Inhibitor-Binding Site. J. Am. Chem. Soc. 145, 16669\u201316677 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"54462_CR44","doi-asserted-by":"publisher","first-page":"10809","DOI":"10.1021\/acs.jmedchem.2c00682","volume":"65","author":"W Liu","year":"2022","unstructured":"Liu, W., Jiang, J., Lin, Y., You, Q. & Wang, L. Insight into Thermodynamic and Kinetic Profiles in Small-Molecule Optimization. J. Med Chem. 65, 10809\u201310847 (2022).","journal-title":"J. Med Chem."},{"key":"54462_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39267-x","volume":"14","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection. Nat. Commun. 14, 3537 (2023).","journal-title":"Nat. Commun."},{"key":"54462_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106708","volume":"61","author":"D Focosi","year":"2023","unstructured":"Focosi, D. et al. Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics. Int J. Antimicrob. Agents 61, 106708 (2023).","journal-title":"Int J. Antimicrob. Agents"},{"key":"54462_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"54462_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40018-1","volume":"14","author":"M Kiso","year":"2023","unstructured":"Kiso, M. et al. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nat. Commun. 14, 4231 (2023).","journal-title":"Nat. Commun."},{"key":"54462_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fchem.2019.00402","volume":"7","author":"C de Bruyn Kops","year":"2019","unstructured":"de Bruyn Kops, C. et al. GLORY: Generator of the Structures of Likely Cytochrome P450 Metabolites Based on Predicted Sites of Metabolism. Front Chem. 7, 402 (2019).","journal-title":"Front Chem."},{"key":"54462_CR50","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/bioinformatics\/btz695","volume":"36","author":"C Stork","year":"2020","unstructured":"Stork, C. et al. NERDD: a web portal providing access to in silico tools for drug discovery. Bioinformatics 36, 1291\u20131292 (2020).","journal-title":"Bioinformatics"},{"key":"54462_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D. Biol. Crystallogr 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"54462_CR52","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1107\/S1600576719001183","volume":"52","author":"F Yu","year":"2019","unstructured":"Yu, F. et al. Aquarium: an automatic data-processing and experiment information management system for biological macromolecular crystallography beamlines. J. Appl. Crystallogr. 52, 472\u2013477 (2019).","journal-title":"J. Appl. Crystallogr."},{"key":"54462_CR53","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr"},{"key":"54462_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","volume":"55","author":"PD Adams","year":"2011","unstructured":"Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94\u2013106 (2011).","journal-title":"Methods"},{"key":"54462_CR55","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"54462_CR56","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1107\/S0907444909029436","volume":"65","author":"NW Moriarty","year":"2009","unstructured":"Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr D. Biol. Crystallogr 65, 1074\u20131080 (2009).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"}],"updated-by":[{"DOI":"10.1038\/s41467-025-56341-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54462-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:44:14Z","timestamp":1737521054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54462"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54462-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.03.587743","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-56341-8","URL":"https:\/\/doi.org\/10.1038\/s41467-025-56341-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10169"}}